{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T09:04:44.444823+00:00","company":{"ticker":"SYRA","cik":1922335,"company_name":"Syra Health Corp"},"pagination":{"limit":100,"returned":17,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"earnings_release","fact_key":"36b4cddc0698af089b00cc4f25bc656313a65720","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"$0.02 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$240,979","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$2.3 million"},"claim":"Syra Health Corp reported first quarter ended March 31, 2026 results: revenue $2.3 million, net income $240,979, EPS $0.02 per share.","evidence_excerpt":"period ● Q1\n 2026 EPS grew to $0.02 per share versus ($0.04) in Q1 2025 ● Gross\n Margin rose to 42.7%, up 11 percentage points year-over-year ● Total\n revenue increased to $2.3 million, up 22% when compared to the prior year period Carmel,\nInd., May 7, 2026 / PRNewswire – Syra Health Corp. (OTCQB: SYRA) (“Syra Health” or the “Company”),\nan integrated healthcare","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-26-021629","anchor_url":"https://secwatch.observer/filing/0001493152-26-021629#claim-36b4cddc0698af089b00cc4f25bc656313a65720","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315226021629/0001493152-26-021629-index.htm"},{"fact_type":"earnings_release","fact_key":"8c18b50c495b7b643567d9642631864eadc22539","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2026-03-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"FY2026","report_date":"2026-03-12","result_type":"guidance_update","revenue_text":null},"claim":"Syra Health Corp updated its FY2026 guidance (initiated).","evidence_excerpt":"2026 Financial Outlook ● The Company expects to achieve profitability by year-end 2026, driven by continued strong demand for its comprehensive population health solutions, disciplined cost management, and new contract wins.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-009799","anchor_url":"https://secwatch.observer/filing/0001493152-26-009799#claim-8c18b50c495b7b643567d9642631864eadc22539","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315226009799/0001493152-26-009799-index.htm"},{"fact_type":"earnings_release","fact_key":"09efc280a750622f6461a4dbeba754906705d507","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2026-03-12T23:59:59+00:00","payload":{"eps_text":"($0.01)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"($135K)","period_text":"Q4 2025","report_date":"2026-03-12","result_type":"reported_results","revenue_text":null},"claim":"Syra Health Corp reported Q4 2025 results: net income ($135K), EPS ($0.01).","evidence_excerpt":"Q4 and Full Year 2025 Financial Highlights ● Population Health revenue grew 157% year-over-year to $5.3 million in FY2025 from $2.1 million in FY2024, driven by demand for the Company's higher margin yielding population health solutions, including data analytics, health education and training. Q4 2025 Population Health revenue grew 128% year-over-year to $1.3 million, compared to $550K in Q4 2024. ● Earnings per share improved by $0.42 in FY2025 to ($0.08) from ($0.50) in FY2024. Q4 2025 EPS improved to ($0.01) from ($0.08) in Q42024, representing meaningful progress as the Company moves closer to profitability. ● Total operating expenses declined 37% to $3.4 million in FY2025 when compared to $5.4 million in FY2024. Q4 2025 operating expenses decreased 13% to $727K from $836K in Q4 2024. ● Net loss improved 76% to ($896K) in FY2025 from ($3.8M) in FY2024. Q4 2025 net loss was reduced 73% to ($135K) versus ($504K) in Q4 2024, reflecting a significantly improved cost structure. ● Gross","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-009799","anchor_url":"https://secwatch.observer/filing/0001493152-26-009799#claim-09efc280a750622f6461a4dbeba754906705d507","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315226009799/0001493152-26-009799-index.htm"},{"fact_type":"earnings_release","fact_key":"b7d8459a0bc749cd09bb167fa9ec8adec43ec812","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2026-03-12T23:59:59+00:00","payload":{"eps_text":"($0.08)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"($896,333)","period_text":"FY2025","report_date":"2026-03-12","result_type":"reported_results","revenue_text":"$7,225,973"},"claim":"Syra Health Corp reported FY2025 results: revenue $7,225,973, net income ($896,333), EPS ($0.08).","evidence_excerpt":"Syra Health Corp Statements of Operations For the Years Ended December 31, 2025 and 2024 December revenues $ 7,225,973 $ 7,982,082 Cost of services 4,738,211 6,329,119 Gross profit 2,487,762 1,652,963 OPERATING EXPENSES: Salaries and benefits 1,500,688 2,718,743 Professional services 737,714 606,051 Research and development expenses 67,840 585,146 Selling, general and administrative expenses 1,065,376 1,445,170 Depreciation 20,468 62,738 Total operating expenses 3,392,086 5,417,848 Net loss from operations (904,324 ) (3,764,885 ) OTHER INCOME (EXPENSES): Interest income 21,261 21,247 Interest expense (13,270 ) (15,600 ) Total other income (expense) 7,991 5,647 NET INCOME (LOSS) $ (896,333 ) $ (3,759,238 ) Loss per common share, basic and diluted $ (0.08 ) $ (0.50 ) Weighted average number of common shares outstanding, basic and diluted 11,852,347 7,551,576","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-009799","anchor_url":"https://secwatch.observer/filing/0001493152-26-009799#claim-b7d8459a0bc749cd09bb167fa9ec8adec43ec812","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315226009799/0001493152-26-009799-index.htm"},{"fact_type":"governance_change","fact_key":"e75d51a5c19f0c836cf89714996e9b391e0cac39","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2025-11-18T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-11-18","item_codes_triggered":["5.03"],"summary_text":"Deleted automatic conversion of Class B Common Stock upon death of stockholder; allowed transfer to immediate family members, heirs, successors, and assigns without conversion."},"claim":"Syra Health Corp: Deleted automatic conversion of Class B Common Stock upon death of stockholder; allowed transfer to immediate family members, heirs, successors, and assigns without conversion (effective 2025-11-18).","evidence_excerpt":"As previously reported, upon the recommendation of the Board of Directors of Syra Health Corp. (the “Company”) the Company’s stockholders approved amendments to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) on November 14, 2025 to (i) delete Article IV, Section 4.2.8(D) in its entirety which allowed for the automatic conversion of Class B Common Stock upon death of a Class B stockholder and (ii) add immediate family members, heirs, successors and assigns as parties to whom the Class B stockholder can transfer shares to without such Class B shares being converted.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-024059","anchor_url":"https://secwatch.observer/filing/0001493152-25-024059#claim-e75d51a5c19f0c836cf89714996e9b391e0cac39","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315225024059/0001493152-25-024059-index.htm"},{"fact_type":"executive_change","fact_key":"2564419e43","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2025-06-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-16","interim":true,"role":"Interim Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Priya Prasad was appointed as Interim Chief Executive Officer at Syra Health Corp.","evidence_excerpt":"the Board of Directors of the Company appointed Priya Prasad, the Company’s CFO and COO, as interim CEO.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-015349","anchor_url":"https://secwatch.observer/filing/0001641172-25-015349#claim-2564419e43","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000164117225015349/0001641172-25-015349-index.htm"},{"fact_type":"executive_change","fact_key":"5f07bbeba1","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2025-05-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-25","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Andrew Dahlem resigned as Director at Syra Health Corp.","evidence_excerpt":"On April 25, 2025, Andrew Dahlem resigned from the Board of Directors of Syra Health Corp. (the “Company”) for personal reasons.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-008103","anchor_url":"https://secwatch.observer/filing/0001641172-25-008103#claim-5f07bbeba1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000164117225008103/0001641172-25-008103-index.htm"},{"fact_type":"earnings_release","fact_key":"d255fc630ac7829ed350db69c7cbdaaf478360b9","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$(1.4 million)","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$1.7 million"},"claim":"Syra Health Corp reported first quarter ended March 31, 2024 results: revenue $1.7 million, net income $(1.4 million). Guidance reaffirmed.","evidence_excerpt":"innovative services and technology solutions, announced\ntoday its financial results for the first quarter ended March 31, 2024. Q1\n2024 Financial Highlights ● Revenue\n of $1.7 million in 1Q24 compared to $1.2 million in 1Q23. ● Business\n units excluding Healthcare Workforce grew 333% and comprised 19% of total revenues in 1Q24, versus only 7% in 1Q23. ●","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-018507","anchor_url":"https://secwatch.observer/filing/0001493152-24-018507#claim-d255fc630ac7829ed350db69c7cbdaaf478360b9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315224018507/0001493152-24-018507-index.htm"},{"fact_type":"executive_change","fact_key":"d011ee9e5e","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2024-03-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-27","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Priya Prasad was appointed as Director at Syra Health Corp.","evidence_excerpt":"On March 27, 2024, the Board of Directors of Syra Health Corp. (the “Company”) appointed Priya Prasad, the Company’s COO and CFO as a director of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-011606","anchor_url":"https://secwatch.observer/filing/0001493152-24-011606#claim-d011ee9e5e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315224011606/0001493152-24-011606-index.htm"},{"fact_type":"earnings_release","fact_key":"f52558179f83e39861fbb267cb36db97e641a107","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2024-03-25T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2024","report_date":"2024-03-25","result_type":"guidance_update","revenue_text":"$9 to $11 million"},"claim":"Syra Health Corp reported full-year 2024 results: revenue $9 to $11 million. Guidance initiated.","evidence_excerpt":"The Company expects full-year 2024 revenue of $9 to $11 million, representing a growth of 64%-100% versus 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-011142","anchor_url":"https://secwatch.observer/filing/0001493152-24-011142#claim-f52558179f83e39861fbb267cb36db97e641a107","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315224011142/0001493152-24-011142-index.htm"},{"fact_type":"earnings_release","fact_key":"2212174111dc7f5b21abb228f598c34c4cf446e6","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2024-03-25T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$(2.94 million)","period_text":"the fourth quarter and fiscal year ended December 31, 2023","report_date":"2024-03-25","result_type":"reported_results","revenue_text":"$5.5 million"},"claim":"Syra Health Corp reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $5.5 million, net income $(2.94 million). Guidance reaffirmed.","evidence_excerpt":"and technology solutions, today\nannounced its financial results for the fourth quarter and fiscal year ended December 31, 2023. 2023\nFinancial Highlights ● 2023\n revenue of $5.5 million compared to $5.6 million in 2022. ● Business\n units excluding Healthcare Workforce grew 250% and comprised 23% of total revenues in 2023, versus only 6% in 2022. ● Population","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-011142","anchor_url":"https://secwatch.observer/filing/0001493152-24-011142#claim-2212174111dc7f5b21abb228f598c34c4cf446e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315224011142/0001493152-24-011142-index.htm"},{"fact_type":"earnings_release","fact_key":"5e53a2ef6bc8e7d8fc42db228d106570aba1e2ca","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2023-11-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(354,376)","period_text":"third quarter of 2023","report_date":"2023-11-14","result_type":"reported_results","revenue_text":"$1.58 million"},"claim":"Syra Health Corp reported third quarter of 2023 results: revenue $1.58 million, net income $(354,376).","evidence_excerpt":"and technology\nsolutions, today announced its financial results for the third quarter of 2023 for the period ended September 30, 2023. Q3\n2023 Financial Highlights ● Revenue\n of $1.58 million, compared to $1.51 million in Q3 2022, an increase of 4%. ● Digital\n Health, driven by sales of the Company’s SyraBot product, had revenue of $131,356, marking its first period","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-23-041118","anchor_url":"https://secwatch.observer/filing/0001493152-23-041118#claim-5e53a2ef6bc8e7d8fc42db228d106570aba1e2ca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315223041118/0001493152-23-041118-index.htm"},{"fact_type":"executive_change","fact_key":"aa942f4c80","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2023-10-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Avutu Reddy was appointed as Director at Syra Health Corp.","evidence_excerpt":"Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-035687","anchor_url":"https://secwatch.observer/filing/0001493152-23-035687#claim-aa942f4c80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315223035687/0001493152-23-035687-index.htm"},{"fact_type":"executive_change","fact_key":"dd502fea75","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2023-10-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ketan Paranjape was appointed as Director at Syra Health Corp.","evidence_excerpt":"Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-035687","anchor_url":"https://secwatch.observer/filing/0001493152-23-035687#claim-dd502fea75","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315223035687/0001493152-23-035687-index.htm"},{"fact_type":"executive_change","fact_key":"830348ea37","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2023-10-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Vijayapal Reddy was appointed as Director at Syra Health Corp.","evidence_excerpt":"Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-035687","anchor_url":"https://secwatch.observer/filing/0001493152-23-035687#claim-830348ea37","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315223035687/0001493152-23-035687-index.htm"},{"fact_type":"executive_change","fact_key":"6453a30865","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2023-10-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Andrew Dahlem was appointed as Director at Syra Health Corp.","evidence_excerpt":"Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-035687","anchor_url":"https://secwatch.observer/filing/0001493152-23-035687#claim-6453a30865","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315223035687/0001493152-23-035687-index.htm"},{"fact_type":"executive_change","fact_key":"d1c136352a","cik":1922335,"ticker":"SYRA","company_name":"Syra Health Corp","filed_at":"2023-10-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Sherron Rogers was appointed as Director at Syra Health Corp.","evidence_excerpt":"Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-035687","anchor_url":"https://secwatch.observer/filing/0001493152-23-035687#claim-d1c136352a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1922335/000149315223035687/0001493152-23-035687-index.htm"}]}